Fracture rate in patients with myasthenia gravis: the general practice research database

被引:14
|
作者
Pouwels, S. [1 ]
de Boer, A. [1 ]
Javaid, M. K. [2 ]
Hilton-Jones, D. [3 ]
Verschuuren, J. [4 ]
Cooper, C. [2 ,5 ]
Leufkens, H. G. [1 ]
de Vries, F. [1 ,5 ,6 ]
机构
[1] Univ Utrecht, Utrecht Inst Pharmaceut Sci, Utrecht, Netherlands
[2] Univ Oxford, Oxford NIHR Musculoskeletal Biomed Res Unit, Dept Orthopaed Rheumatol & Musculoskeletal Sci, Oxford, England
[3] Univ Oxford, Dept Clin Neurol, Oxford, England
[4] Leiden Univ, Med Ctr, Dept Neurol, Leiden, Netherlands
[5] Univ Southampton, MRC Lifecourse Epidemiol Unit, Southampton, Hants, England
[6] Maastricht Univ, Med Ctr, Dept Clin Pharm & Toxicol, Maastricht, Netherlands
关键词
Corticosteroids; Epidemiology; Fracture; Myasthenia gravis; Osteoporosis; ORAL CORTICOSTEROIDS; RISK; FALLS; ANTIDEPRESSANTS; POPULATION; DRUGS; VALIDATION; DENSITY; WOMEN; MEN;
D O I
10.1007/s00198-012-1970-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The aim of this study was to evaluate fracture risk after onset of myasthenia gravis using the UK General Practice Research Database. Overall fracture risk is not statistically increased compared with age- and gender-matched controls irrespective of glucocorticoid use, but was increased in those using antidepressants, anxiolytics or anticonvulsants. Myasthenia gravis (MG) is a neuromuscular disease which has been associated with an increased falls risk and glucocorticoid-induced osteoporosis, recognized determinants of increased fracture risk. The aim of this study was to evaluate the risk of fracture after onset of MG. We conducted a retrospective cohort study using the UK General Practice Research Database (1987-2009). Each MG patient was matched by age, sex, calendar time and practice to up to six patients without a history of MG and we identified all fractures and those associated with osteoporosis. Compared to the control cohort, there was no statistically significant increased risk observed in patients with MG for any fracture (adjusted hazard ratio [AHR] 1.11; 95 % confidence interval [CI], 0.84-1.47) or osteoporotic fractures (AHR 0.98 [95 % CI 0.67-1.41]). Further, use of oral glucocorticoids up to a cumulative dose exceeding 5 g prednisolone equivalents did not increase risk of osteoporotic fracture (AHR 0.99 [95 % CI, 0.31-3.14]) compared with MG patients without glucocorticoid exposure. However, fracture risk was higher in patients with MG prescribed antidepressants (AHR 3.27 [95 % CI, 1.63-6.55]), anxiolytics (AHR 2.18 [95 % CI, 1.04-4.57]) and anticonvulsants (AHR 6.88 [95 % CI, 2.91-16.27]). Overall risk of fracture in patients with MG is not statistically increased compared with age- and gender-matched controls irrespective of glucocorticoid use but was increased in those using antidepressants, anxiolytics or anticonvulsants. These findings have implications in strategies preserving bone health in patients with MG.
引用
收藏
页码:467 / 476
页数:10
相关论文
共 50 条
  • [31] Determination of pregnancy on the General Practice Research Database
    Snowball, Julia M.
    de Vries, Corinne S.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2007, 16 : S118 - S119
  • [32] The general, practice research database - Role in pharmacovigilance
    Wood, L
    Martinez, C
    DRUG SAFETY, 2004, 27 (12) : 871 - 881
  • [33] Validity of diagnoses in the General Practice Research Database
    Herrett, Emily L.
    Thomas, Sara L.
    Smeeth, Liam
    BRITISH JOURNAL OF GENERAL PRACTICE, 2011, 61 (588): : 438 - 439
  • [34] General Practice Research Database for prescribing analysis
    Frischer, M
    Chapman, S
    Bashford, F
    Norwood, J
    Heatlie, H
    LANCET, 1998, 351 (9100): : 453 - 454
  • [35] Myasthenia gravis in older patients
    Meenakshisundaram, Sanjeevikumar
    AGE AND AGEING, 2006, 35 (05) : 542 - 542
  • [36] Fatigue in patients with myasthenia gravis
    T. M. Alekseeva
    Y. V. Gavrilov
    O. A. Kreis
    P. O. Valko
    K. P. Weber
    Y. Valko
    Journal of Neurology, 2018, 265 : 2312 - 2321
  • [37] Anaesthesia in patients with myasthenia gravis
    Blobner, M
    Mann, R
    ANAESTHESIST, 2001, 50 (07): : 484 - 493
  • [38] Sugammadex in patients with myasthenia gravis
    de Boer, H. D.
    van Egmond, J.
    Driessen, J. J.
    Booij, L. H. J. D.
    ANAESTHESIA, 2010, 65 (06) : 653 - 653
  • [39] Fracture Risk in Patients with Myasthenia Gravis: A Population-Based Cohort Study
    Kassardjian, Charles
    Widdifield, Jessica
    Paterson, J. Michael
    Kopp, Alexander
    Nagamuthu, Chenthila
    Barnett, Carolina
    Tu, Karen
    Breiner, Ari
    JOURNAL OF NEUROMUSCULAR DISEASES, 2021, 8 (04) : 625 - 632
  • [40] GENERAL DISCUSSION ON THERAPY IN MYASTHENIA-GRAVIS
    ROWLAND, LP
    DRACHMAN, DB
    OLANOW, CW
    FOLDES, FF
    JOHNS, TR
    SEYBOLD, ME
    MATTEL, G
    PENN, AS
    LISAK, RP
    SWIFT, TR
    TOYKA, KV
    COREY, A
    RAPPAPORT, S
    SCHALKE, BCG
    ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1987, 505 : 607 - 609